NCT03557281View on ClinicalTrials.gov

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

December 3, 2021

Study Completion Date

December 14, 2021

Conditions

Tuberculosis

Interventions

DRUG

GSK3036656

GSK3036656 will be administered

DRUG

Rifafour e-275

Rifafour e-275 will be administered

Trial Locations (1)

7530

GSK Investigational Site, Cape Town

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY